A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Public ClinicalTrials.gov record NCT01287039. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.
Study identification
- NCT ID
- NCT01287039
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 489 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 2011 (Type not available)
- Primary completion
- Dec 2013 (Actual)
- Completion
- Mar 2014 (Actual)
- Last update posted
- Nov 9, 2021
2011 – 2014
United States locations
- U.S. sites
- 26
- U.S. states
- 18
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 58 | Scottsdale | Arizona | — | — |
| Teva Investigational Site 61 | Los Angeles | California | — | — |
| Teva Investigational Site 37 | Orange | California | — | — |
| Teva Investigational Site 56 | San Diego | California | — | — |
| Teva Investigational Site 34 | Colorado Springs | Colorado | — | — |
| Teva Investigational Site 52 | DeBary | Florida | — | — |
| Teva Investigational Site 55 | Miami | Florida | — | — |
| Teva Investigational Site 18 | Valrico | Florida | — | — |
| Teva Investigational Site 49 | Lexington | Kentucky | — | — |
| Teva Investigational Site 65 | Louisville | Kentucky | — | — |
| Teva Investigational Site 51 | Boston | Massachusetts | — | — |
| Teva Investigational Site 74 | St Louis | Missouri | — | — |
| Teva Investigational Site 35 | Missoula | Montana | — | — |
| Teva Investigational Site 64 | Boys Town | Nebraska | — | — |
| Teva Investigational Site 68 | Rochester | New York | — | — |
| Teva Investigational Site 60 | The Bronx | New York | — | — |
| Teva Investigational Site 30 | Winston-Salem | North Carolina | — | — |
| Teva Investigational Site 31 | Cincinnati | Ohio | — | — |
| Teva Investigational Site 62 | Columbus | Ohio | — | — |
| Teva Investigational Site 50 | Oklahoma City | Oklahoma | — | — |
| Teva Investigational Site 66 | Altoona | Pennsylvania | — | — |
| Teva Investigational Site 32 | Nashville | Tennessee | — | — |
| Teva Investigational Site 63 | Boerne | Texas | — | — |
| Teva Investigational Site 72 | Houston | Texas | — | — |
| Teva Investigational Site 38 | Richmond | Virginia | — | — |
| Teva Investigational Site 33 | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 102 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01287039, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 9, 2021 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01287039 live on ClinicalTrials.gov.